Skip to content

Price / earnings at other companies

Amgen logo
AmgenAMGN
24.3×-3.9×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
3.7×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.4×
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
100.4×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
105.5×
Theravance Biopharma logo
Theravance BiopharmaTBPH
7.3×

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's price / earnings?
Rigel Pharmaceuticals (RIGL) reported price / earnings of 1.4× in Q1 2026.
How has Rigel Pharmaceuticals's price / earnings changed year-over-year?
Rigel Pharmaceuticals's price / earnings decreased by 84.1% year-over-year, from 8.6× to 1.4×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.